Gilead gets strong FDA panel support for hepatitis C drug
This article was originally published in Scrip
Gilead Sciences’ hepatitis C drug sofosbuvir should be approved to treat multiple forms of the virus, including the most common type in the US, a panel of FDA advisers unanimously agreed.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.